Spotlight -

Long-Acting Injectable Therapy in the Management of Adult Patients with Schizophrenia|

Major Depressive Disorder

|Slideshows|October 11, 2018

6 Myths About Integrative Psychiatry

Author(s)Scott Shannon, MD

As we shift from treating disease and toward supporting health, medication is merely one possible intervention in a spectrum of possible ones.

Newsletter

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Related Content

kratom

Kratom Component in Clinical Trial for Opioid Use Disorder

ByKenneth J. Bender, PharmD, MA

August 21st 2026

opioids

A Practical Role for Long-Acting Buprenorphine in Opioid Use Disorder Care

ByChristian Heidbreder, PhD

August 20th 2026

drug testing

Let’s Talk About Drug Testing

ByEvan S. Schwarz, MD, FACEP, FACMT, FASAM

August 19th 2026

stuttering

Psychiatry and the Treatment of Stuttering: A Blossoming Partnership

ByMike Hennessy Jr

August 11th 2026

brain

Interdisciplinary Consensus Guidelines on Stuttering (Childhood-Onset Fluency Disorder): Addressing Issues in Diagnosis, Treatment, and Unmet Needs

ByGerald A. Maguire, MD,Heidi Anne Duerr, MPH,Shahriar SheikhBahaei, PhD,Yoshikazu Kikuchi, MD, PhD,Lisa LaSalle PhD, CCC-SLP,Thomas J. Valente, MD,Anelise Junqueira Bohne, PhD, SLP,Tiago Proença dos Santos, MD,Gonçalo Leal, SLP,Devin Binder, MD, PhD,Gustavo Alva, MD, DFAPA,Greg Mattingly, MD

August 10th 2026

Latest CME

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Jersey City Psychiatry

In-Person Event

Jersey City Psychiatry

October 2-3, 2026

Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Patricia Junquera, MD; Maria Collado, MD; Erin C. Crown, MHSPAS, PA-C, Psych-CAQ

Trending on Psychiatric Times

FDA Clears First and Only Single-Biomarker Blood Test for Alzheimer Disease Assessment

Patent Application Published: MDMA-N-Acylethanolamines for the Treatment of PTSD, Anxiety, and Eating Disorders

Kratom Component in Clinical Trial for Opioid Use Disorder

Migraine and Psychiatric Comorbidities

NIDA Awards PleoPharma $6.5 Million Grant to Advance Phase 3 Trial of PP-01 for Cannabis Use Disorder